Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Hyperoxaluria Type 3 (PH3)”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Early research (Phase 1)Study completedNCT04555486
What this trial is testing

Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

Who this might be right for
Primary Hyperoxaluria Type 3
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 6
Testing effectiveness (Phase 2)Study completedNCT05001269
What this trial is testing

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function

Who this might be right for
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 2+1 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 27
Large-scale testing (Phase 3)Active Not RecruitingNCT04042402
What this trial is testing

Long Term Extension Study in Patients With Primary Hyperoxaluria

Who this might be right for
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney Diseases+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 75
Not applicableStudy completedNCT04542590
What this trial is testing

Natural History of Patients With PH3 and a History of Stone Events

Who this might be right for
Primary Hyperoxaluria Type 3
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 7